PD-L1 expression, which is the only comparable clinical predictor of a response to anti-PD-1/PD-L1 antibody monotherapy in patients with advanced NSCLC, remains to be related with clinical outcomes of ICIs-based combination therapy. The gene discussed is CD274; the disease is non-small cell lung carcinoma.